Evaluation of the prevalence of cyclic citrullinated peptide antibody (CCP) in patients with inflammatory bowel disease
Introduction: Arthritis is the most prevalent extra intestinal presentation of IBD that consists of central and peripheral arthritis. Patients with IBD express strong antibodies against various epitopes. Many studies showed anti CCP as diagnostic hallmark for RA and believe its role in the pathogenesis of RA. Positive anti CCP test has been shown in patients with rheumatologic manifestation such as JIA, systemic sclerosis andSjogren'ssyndrome. Regarding that IBD is one of rheumatologic diseases with articular presentation and also few studies about the prevalence of anti CCP has been performed up to now, So we are prompted to do this study to determine the prevalence of this anti body in patients with IBD. Method: This descriptive cross-sectional study was performed from September 2010 to September 2011. Study population was known patients with IBD based true love criteria which referred to gastroenterologists’ office in Rasht city. Patients were selected by easy sampling method. Some diagnostic tests including CBC, ESR, Anti CCP … were performed and a questionnaire consistent of demographic information, lab test result and clinical criteria including articular manifestation (erythema, warmness and motion limitation), eye manifestation (eye redness), skin manifestation (erythema nodosum, pyodermagangrenosum were completed for patients. After being collected, the data were analyzed by SPSS software. Results: Out of 144 patients, 13 cases were Anti CCP positive (9. 02%). In this study, there was no statistically significant association between the prevalence of Anti CCP and age, gender, times of defecation, amount of blood in stool, body temperature, Heart rate, anemia, arthralgia, arthritis, skin manifestation, ESR, endoscopic feature, whereas there were a significant association between the prevalence of Anti CCP and eye manifestation (0.001) and oral aphthous (0. 014), as the prevalence was greater in patients with eye presentation and oral aphthous.